CSIMarket Company Name, Ticker, Customers, else..
 
Pulmonx Corporation  (NASDAQ: LUNG)
 
Price: $1.8600 $0.01 0.541%
Day's High: $2.005000114440918 Week Perf: -15.84 %
Day's Low: $ 1.82 30 Day Perf: -18.78 %
Volume (M): 98,896 52 Wk High: $ 2.89
Volume (M$): $ 0 52 Wk Avg: $1.69
Open: $1.85 52 Wk Low: $1.13



 Market Capitalization (Millions $) 79
 Shares Outstanding (Millions) 42
 Employees 296
 Revenues (TTM) (Millions $) 87
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Business Description


Pulmonx Corporation is a medical technology company that specializes in developing and commercializing minimally invasive solutions for patients with severe lung diseases. The company focuses on providing innovative treatments for conditions such as chronic obstructive pulmonary disease (COPD) and severe emphysema. Its flagship product is the Zephyr Valve system, which is designed to improve lung function by blocking off diseased lung regions and allowing healthier lung tissue to function more effectively. Pulmonx Corporation is dedicated to improving the quality of life for patients with lung diseases by offering less invasive and highly effective treatment options.


   Company Address: 700 Chesapeake Drive Redwood City 94063 CA
   Company Phone Number: 364-0400   Stock Exchange / Ticker: NASDAQ LUNG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANGO   -1.23%    
EW   -5.11%    
ISRG   -0.38%    
MDT   -2.35%    
PRCT   -5.4%    
TFX   -7.75%    
• View Complete Report
   



Clinical Study

Pulmonx Bolsters COPD Treatment with Groundbreaking AeriSeal Data at ERS Congress 2024 77.6% Patient ...

Published Mon, Sep 9 2024 8:05 PM UTC

Pulmonx Unveils Groundbreaking Data on AeriSeal System at the European Respiratory Society Congress 2024 In a significant advance for patients suffering from chronic obstructive pulmonary disease (COPD), Pulmonx Corporation, a leader in the field of lung volume reduction technologies, has announced the presentation of pivotal clinical data from the AeriSeal CONVERT trial as ...
Financing Agreement

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer

Published Mon, May 6 2024 9:03 PM UTC

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer
Pulmonx Corporation, a leading global provider of minimally invasive treatments for lung disease, recently announced the granting of inducement awards to Mehul Joshi, who was appointed as the company s Chief Financial Officer in April 2024. The awards, approved by the Compensation Committee of th...
Management Changes

Pulmonx Corporation Instills Financial Expertise with New CFO Appointment, Aiming for Future Recovery and Innovation

Published Tue, Apr 2 2024 8:05 PM UTC

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer: Assessing the Company s Financial Situation and Future Prospects
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, has recently appointed Mehul Joshi as its new Chief Financial Officer. The appointment comes after Pulmonx recorded a cumulative net loss of $-61 million...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.90
Price to Sales (Expected) -
Price to Book 2.02
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.76
Working Capital Ratio 4.5
Leverage Ratio (MRQ) 1.93
Total Debt to Equity 1.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.17 $
Revenues (TTM) 2.06 $
Cash Flow (TTM) -
Cash 1.33 $
Book Value 0.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 295,247
Net Income per Employee (TTM) -162,554
Receivable Turnover Ratio (TTM) 7.14
Inventory Turnover Ratio (TTM) 1.24
Asset Turnover Ratio (TTM) 0.7

Profitability Ratios Current
Gross Margin (MRQ) 77.97 %
Operating Margin (MRQ) -39.8 %
Net Margin (MRQ) -44.3 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Pulmonx's Segments
United States    120.54 % of total Revenue
EMEA    62.84 % of total Revenue
Asia Pacific    6.3 % of total Revenue
Other International    0.78 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.